Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination therapy for carbapenem-resistant Gram-negative bacteria.
Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. Paul M, et al. Among authors: theuretzbacher u. J Antimicrob Chemother. 2014 Sep;69(9):2305-9. doi: 10.1093/jac/dku168. Epub 2014 May 28. J Antimicrob Chemother. 2014. PMID: 24872346 Review.
Reviving old antibiotics.
Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, Turnidge JD, Kahlmeter G. Theuretzbacher U, et al. J Antimicrob Chemother. 2015 Aug;70(8):2177-81. doi: 10.1093/jac/dkv157. Epub 2015 Jun 10. J Antimicrob Chemother. 2015. PMID: 26063727 Review.
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M; AIDA consortium. Dickstein Y, et al. Among authors: theuretzbacher u. BMJ Open. 2016 Apr 20;6(4):e009956. doi: 10.1136/bmjopen-2015-009956. BMJ Open. 2016. PMID: 27098822 Free PMC article. Clinical Trial.
Antibiotic innovation for future public health needs.
Theuretzbacher U. Theuretzbacher U. Clin Microbiol Infect. 2017 Oct;23(10):713-717. doi: 10.1016/j.cmi.2017.06.020. Epub 2017 Jun 24. Clin Microbiol Infect. 2017. PMID: 28652114 Free article. Review.
β-lactam prolonged infusion: it's time to implement!
Paul M, Theuretzbacher U. Paul M, et al. Among authors: theuretzbacher u. Lancet Infect Dis. 2018 Jan;18(1):13-14. doi: 10.1016/S1473-3099(17)30614-X. Epub 2017 Nov 5. Lancet Infect Dis. 2018. PMID: 29102323 No abstract available.
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Tacconelli E, et al. Among authors: theuretzbacher u. Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21. Lancet Infect Dis. 2018. PMID: 29276051
78 results